Study of a new drug for serious lung failure from infection
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called GKL-006RTU for people with moderate to severe ARDS caused by an infection. The goal is to see if it is safe and helps improve breathing and recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- You must have a lung infection that caused a serious breathing problem called ARDS (a condition where the lungs fill with fluid).
- The breathing problem must be moderate to severe, meaning you need oxygen support (like a breathing machine or high-flow oxygen).
- You must have been receiving active treatment for at least 24 hours, such as antibiotics and lung-protective breathing support.
- You cannot have certain infections like active hepatitis B, hepatitis C, HIV, or syphilis.
- You cannot have serious heart, kidney, liver, or bleeding problems, or be on an ECMO machine (a heart-lung bypass device).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This early-stage trial tests whether an inhaled medication called recombinant human keratinocyte growth factor-2 (rh-KGF-2) can help patients with acute respiratory distress syndrome (ARDS)—a serious condition where the lungs cannot deliver enough oxygen to the blood. The drug is designed to help repair lung tissue damage.
This study looks at how the immune system responds in people with ARDS (a severe lung injury) and tests a new treatment called PIP-2 in the lab to see if it might help. It aims to better understand lung injury and find new ways to treat it.
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
This trial tests a new medicine called YD0743 for people who have both sepsis (a serious infection) and ARDS (a severe lung injury from the infection). The goal is to see if the medicine helps improve breathing and survival.
This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.
Hear when a new ARDS (Acute Respiratory Distress Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.